Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 217Neoplasms 196Carcinoma, Non-Small-Cell Lung 94Colorectal Neoplasms 92Prostatic Neoplasms 79Lung Neoplasms 74Multiple Myeloma 49Head and Neck Neoplasms 48Neoplasm Metastasis 46Melanoma 46Pancreatic Neoplasms 44Leukemia, Myeloid, Acute 41Carcinoma, Hepatocellular 41Recurrence 35Brain Neoplasms 35Squamous Cell Carcinoma of Head and Neck 34Ovarian Neoplasms 32Glioblastoma 30Uterine Cervical Neoplasms 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 28Sarcoma 27Glioma 27Lymphoma, Non-Hodgkin 26Lymphoma 26Stomach Neoplasms 25Carcinoma, Renal Cell 25Lymphoma, Follicular 24Colonic Neoplasms 24Motor Activity 22Esophageal Neoplasms 22

Interventions

enzalutamide 1abiraterone 1Prednisone 1Goserelin 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Castrate Sensitive Prostate Cancer × 90 days × Clear all
NCT03860987 2026-05-22

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
12 enrolled
Genitourinary

Castrate Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡